Oncology Institute reaffirms FY25 revenue view $460M-$480M

Reaffirms FY25 gross profit view $73M-$82M. Reaffirms FY25 free cash flow view (21M)-(12M). The company also continues to see FY25 adjusted EBITDA of (17M)-(8M). The company adds that given revenue growth in the first half of the year, it currently believes it can reach the higher-end of the revenue guidance range for 2025. CEO Daniel Virnich commented, “The momentum we’re seeing in new contract signings, combined with continued strength in pharmacy, gives us increasing confidence that we’ll achieve revenue at the high end of our guidance range for the year and achieve adjusted EBITDA positivity as we exit 2025.”